These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2975971

  • 1. Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts.
    Schölkens BA, Linz W.
    Clin Exp Hypertens A; 1988; 10(6):1259-70. PubMed ID: 2975971
    [Abstract] [Full Text] [Related]

  • 2. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W, Martorana PA, Schölkens BA.
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [Abstract] [Full Text] [Related]

  • 3. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.
    Linz W, Schölkens BA, Kaiser J, Just M, Qi BY, Albus U, Petry P.
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):873-82. PubMed ID: 2535056
    [Abstract] [Full Text] [Related]

  • 4. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist.
    Schölkens BA, Linz W, König W.
    J Hypertens Suppl; 1988 Dec; 6(4):S25-8. PubMed ID: 2853732
    [Abstract] [Full Text] [Related]

  • 5. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.
    Linz W, Schölkens BA.
    J Cardiovasc Pharmacol; 1987 Dec; 10 Suppl 7():S75-82. PubMed ID: 2485067
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts.
    Linz W, Schölkens BA, Han YF.
    J Cardiovasc Pharmacol; 1986 Dec; 8 Suppl 10():S91-9. PubMed ID: 2438498
    [Abstract] [Full Text] [Related]

  • 7. [ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].
    Schölkens BA, Linz W.
    Klin Wochenschr; 1991 Dec; 69 Suppl 24():1-5. PubMed ID: 1865630
    [Abstract] [Full Text] [Related]

  • 8. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart.
    Xiang JZ, Linz W, Becker H, Ganten D, Lang RE, Schölkens B, Unger T.
    Eur J Pharmacol; 1985 Jul 17; 113(2):215-23. PubMed ID: 2995065
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
    Linz W, Wiemer G, Schölkens BA.
    Diabetes; 1996 Jan 17; 45 Suppl 1():S51-8. PubMed ID: 8529801
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart.
    Kozlovski VI, Lomnicka M, Jakubowski A, Chlopicki S.
    Pharmacol Rep; 2007 Jan 17; 59(4):421-7. PubMed ID: 17901571
    [Abstract] [Full Text] [Related]

  • 13. Effects of endothelin on isolated ischaemic rat hearts during ramiprilat, bradykinin and indomethacin perfusion.
    Linz W, Albus U, Schölkens BA.
    J Hypertens Suppl; 1989 Dec 17; 7(6):S310-1. PubMed ID: 2698945
    [Abstract] [Full Text] [Related]

  • 14. Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts.
    Hatta E, Maruyama R, Marshall SJ, Imamura M, Levi R.
    J Pharmacol Exp Ther; 1999 Mar 17; 288(3):919-27. PubMed ID: 10027827
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation.
    Erşahin C, Simmons WH.
    J Cardiovasc Pharmacol; 1997 Jul 17; 30(1):96-101. PubMed ID: 9268227
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose treatment with perindopril on cardiac function in stroke-prone spontaneously hypertensive rats: role of bradykinin.
    Gohlke P, Kuwer I, Bartenbach S, Schnell A, Unger T.
    J Cardiovasc Pharmacol; 1994 Sep 17; 24(3):462-9. PubMed ID: 7528303
    [Abstract] [Full Text] [Related]

  • 17. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?
    Shimada Y, Avkiran M.
    J Cardiovasc Pharmacol; 1996 Mar 17; 27(3):428-38. PubMed ID: 8907806
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
    Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T.
    Hypertension; 1994 Apr 17; 23(4):411-8. PubMed ID: 8144208
    [Abstract] [Full Text] [Related]

  • 19. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
    Schölkens BA, Linz W.
    Clin Physiol Biochem; 1990 Apr 17; 8 Suppl 1():33-43. PubMed ID: 2147878
    [Abstract] [Full Text] [Related]

  • 20. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
    Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N, Lamontagne D.
    Can J Physiol Pharmacol; 2005 Feb 17; 83(2):166-73. PubMed ID: 15791290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.